Company Overview

Medexus is a leading orphan drug and rare disease pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.

GRAFAPEX, an alkylating drug indicated for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation, represents a significant growth opportunity for Medexus. This is driven by its potential to address unmet needs in transplant medicine and expand the company's presence within hematology-oncology. With increasing adoption across transplant centers, GRAFAPEX could become a key driver of revenue growth and long-term value creation for the company.

Medexus Schedules Second Fiscal Quarter 2027 Conference Call

Nov 3 2026, 5:27 PM EST

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Sep 24 2026, 5:30 PM EDT

Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date

Aug 10 2026, 5:30 PM EDT

Management Team

Ken d'Entremont
Chief Executive Officer and Director

Brendon Buschman
Chief Financial Officer

Theresa Ankamah
Vice President, Head of Medical Affairs

Dina Inverso
Vice President of Commercial Strategy

Toshiye Ishisaka
Vice President, Global Operations and Compliance

Ata Miyar
Head of Business Development

Khaled M. Mohamed
Senior Director, Global Regulatory Affairs and Pharmacovigilance

William T. Poncy, MBA
Senior Vice President, Commercial Operations

Maheen Vayani
Vice President, Finance

Meaghan Wasylyk
Vice President, Human Resources

Ian C Wildgoose Brown
General Counsel

Medexus Pharmaceuticals, Inc.

10 King Street East, Suite 600
Toronto, ON M5C 1C3
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.